Inbunden, Engelska, 2026
2 168 kr
Kommande
Edited byFrancesco Maisano, MD, FESC, FHFAHead of Cardiac Surgery and Director of the Valve Center, IRCCS San Raffaele Hospital, Milan, ItalyFabien Praz, MDInterventional Cardiologist and Associate Professor, Bern University Hospital, SwitzerlandMarianna Adamo, MD, PhDInterventional Cardiologist, Heart Failure Physician, and Associate Professor, University of Brescia, ItalyRoberto M. Lang, MD, FASEFormerly Director of the Cardiac Noninvasive Imaging Laboratory and the A.J. Carlson Professor of Medicine, University of Chicago, Chicago, IL, USAYoshinobu Onuma, MD, PhDProfessor in Interventional Cardiology Medical Director, CORRIB Core Laboratory, University of Galway, IrelandTsung-Ying Tsai, MD, PhDClinical Scientist, Boston Scientific, Galway, IrelandMartin B. Leon, MDDirector of the Center for Interventional Vascular Therapy, New York-Presbyterian/ Columbia University Irving Medical Center, New York, NY, USAPatrick W. Serruys, MD, PhD, eFESC, FACCEstablished Professor of Interventional Medicine and Innovation, NUI Galway Senior Consultant, CORRIB Research Centre for Advanced Imaging and Core Laboratory College of Medicine, Nursing and Health Sciences, University of Galway, IrelandAssociate EditorsPruthvi T.C. Revaiah, MD, DM, PhDCHIP Fellow at Icahn School of Medicine at Mount Sinai, New York, NY, USAAishwarya GuravResearch Assistant, University of Galway, IrelandTricuspid Valve Regurgitation is a common valvular pathology, estimated to affect 1.6 million people in the US alone. Even though guidelines recommend either medical therapy or surgical treatment, the misconception of the disorder as a benign disease (along with the high mortality rates of surgical intervention) has led to undertreatment of this disease and description of it as a “forgotten” valve. This text from international experts looks at the disease and the developing transcatheter interventions withpromising potential for use in the clinical setting.